The in vitro activities of doripenem against 364 anaerobic isolates were measured and compared to those of ertapenem, imipenem, meropenem, ceftriaxone, and levofloxacin. All of the carbapenems were active against nearly all Bacteroides fragilis group isolates. Doripenem was either comparable to or slightly less active than imipenem and meropenem against most isolates but more active than the other penems against Clostridium difficile. Doripenem appears to have excellent activity against a broad range of anaerobes.Doripenem, a 1--methyl carbapenem being developed for the treatment of serious systemic bacterial infections, is resistant to hydrolysis by dihydropeptidase 1 (7). In aerobes, doripenem appears to have the advantages of both imipenem (in its activity against gram-positive cocci) and meropenem (in its activity against gram-negative organisms) (12). Metalloenzymes that hydrolyze carbapenems have been found in both aerobic bacteria (3, 10, 11) and anaerobic bacteria (2); the gene for the metalloenzyme may be silent or expressed to various degrees, resulting in a wide range of carbapenem resistance levels (13). In Japan, this accounts for the 2 to 4% rate of resistance to imipenem (1, 16), but these isolates are rarely found in the United States. The purpose of this study was to measure the efficacy of doripenem against a wide range of clinical anaerobic isolates and to compare its in vitro activities to those of other antimicrobial agents.Bacteria were clinical isolates collected from a wide range of infections throughout the United States or worldwide and identified at the Wadsworth Anaerobe Laboratory (5). MICs were determined by the CLSI (formerly NCCLS)-approved Wadsworth agar dilution technique (8). Antimicrobial agents were obtained from the following companies: doripenem (Shionogi & Co., Ltd., Osaka, Japan), imipenem and ertapenem (Merck, Rahway, NJ), meropenem (AstraZeneca, Waltham, MA), ceftriaxone (Hoffman La Roche, Nutley, NJ), and levofloxacin (Johnson and Johnson, Raritan, NJ). For analysis purposes, the bacteria tested were placed in species or genus groups with Ͼ5 isolates, and the MIC ranges, mean geometric MICs, MIC 50 s, and MIC 90 s were reported. Susceptible (intermediate) breakpoints are indicated in Table 1.Efflux inhibitor studies were performed by the spiral gradient endpoint system (19,20) by first depositing a uniform concentration of efflux inhibitor on 15 mm brucella blood agar plates (Anaerobe Systems), resulting in the following concentrations: carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Sigma), 12.5 g/ml; CCCP, 25 g/ml; MC 207,110 (Sigma), 100 g/ml, reserpine (Sigma), 25 g/ml; and verapamil (Sigma), 100 g/ml. Doripenem was then deposited in the gradient mode, and MICs were determined. The concentrations of efflux inhibitors chosen were not inhibitory for the strains.Doripenem was active against almost all strains of the Bacteroides fragilis group of organisms. Doripenem had MICs of 16 g/ml for one strain and MICs of 8 g/ml for three additional strains. The MICs of the o...